IE 11 is not supported. For an optimal experience visit our site on another browser.

Judge Orders Separate Murder Trials in Fungal Meningitis Case

Two men facing multiple murder charges stemming from a national meningitis outbreak in 2012 that killed 64 people will be tried separately.
Image: Glenn Adam Chin
In this Sept. 11, 2014 photo, Glenn Adam Chin, former supervisory pharmacist at the New England Compounding Center, departs federal court in Boston. Steven Senne / AP FILE
/ Source: The Associated Press

Two men facing multiple murder charges stemming from a national meningitis outbreak in 2012 that killed 64 people will be tried separately, a federal judge has ruled.

U.S. District Court Judge Richard Stearns said in his decision last week that he severed the trials of Barry Cadden and Glenn Chin reluctantly because their lawyers plan "antagonistic" defenses and because of an "imbalance of evidence."

Image: Glenn Adam Chin
In this Sept. 11, 2014 photo, Glenn Adam Chin, former supervisory pharmacist at the New England Compounding Center, departs federal court in Boston. Steven Senne / AP FILE

Cadden was the co-founder and head pharmacist of the New England Compounding Center in Framingham, while Chin was supervisory pharmacist at the now-closed business.

Related: Fungal Meningitis Victims Get $100 Million Settlement

The compounding center used expired ingredients and failed to follow cleanliness standards, resulting in tainted steroid injections, prosecutors said. More than 750 people in 20 states became ill. Sixty-four died.

Cadden and Chin are each charged with 25 counts of second-degree murder and other offenses under federal racketeering laws.

Related: Massachusetts Pharmacist Arrested Trying to Leave Country

Lawyers for both men have said federal prosecutors overreached in charging them with murder. Both have pleaded not guilty and are free on bail.

Cadden's lawyers filed the motion for separate trials this month. The motion remains under seal.

Cadden's trial is scheduled to start Jan. 4. Chin's trial will begin immediately afterward.

Related: FDA Says Fungal Meningitis Outbreak Could Happen Again